PuSH - Publication Server of Helmholtz Zentrum München

Papewalis, C.* ; Kouatchoua, C.* ; Ehlers, M.* ; Jacobs, B.* ; Porwol, D.* ; Schinner, S.* ; Willenberg, H.S.* ; Anlauf, M.* ; Raffel, A.* ; Eisenhofer, G.* ; Neumann, H.P.* ; Bornstein, S.R.* ; Scherbaum, W.A.* ; Schott, M.*

Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma.

Mol. Cell. Endocrinol. 335, 69-77 (2011)
DOI Order publishers version
Open Access Green as soon as Postprint is submitted to ZB.
Currently, no effective treatment for malignant pheochromocytoma exists. The aim of our study was to investigate the role of chromogranin A (CgA) as a specific target molecule for immunotherapy in a murine model for pheochromocytoma. Six amino acid-modified and non-modified CgA peptides were used for dendritic cell vaccination. Altogether, 50 mice received two different CgA vaccination protocols; another 20 animals served as controls. In vitro tetramer analyses revealed large increases of CgA-specific cytotoxic T cells (CTL) in CgA-treated mice. Tumors of exogenous applied pheochromocytoma cells showed an extensive infiltration by CD8+ T cells. In vitro, CTL of CgA-treated mice exhibited strong MHC I restricted lysis capacities towards pheochromocytoma cells. Importantly, these mice showed strongly diminished outgrowth of liver tumors of applied pheochromocytoma cells. Our data clearly demonstrate that CgA peptide-based immunotherapy induces a cytotoxic immune response in experimental pheochromocytoma, indicating potential for therapeutic applications in patients with malignant pheochromocytoma.
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
ISSN (print) / ISBN 0303-7207
e-ISSN 1872-8057
Quellenangaben Volume: 335, Issue: 1, Pages: 69-77 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place Shannon
Reviewing status Peer reviewed
Institute(s) Institute for Pancreatic Beta Cell Research (IPI)